Zhang Yanmin, Jiao Yu, Xiong Xiao, Liu Haichun, Ran Ting, Xu Jinxing, Lu Shuai, Xu Anyang, Pan Jing, Qiao Xin, Shi Zhihao, Lu Tao, Chen Yadong
Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Mol Divers. 2015 Nov;19(4):895-913. doi: 10.1007/s11030-015-9592-4. Epub 2015 May 29.
The discovery of novel scaffolds against a specific target has long been one of the most significant but challengeable goals in discovering lead compounds. A scaffold that binds in important regions of the active pocket is more favorable as a starting point because scaffolds generally possess greater optimization possibilities. However, due to the lack of sufficient chemical space diversity of the databases and the ineffectiveness of the screening methods, it still remains a great challenge to discover novel active scaffolds. Since the strengths and weaknesses of both fragment-based drug design and traditional virtual screening (VS), we proposed a fragment VS concept based on Bayesian categorization for the discovery of novel scaffolds. This work investigated the proposal through an application on VEGFR-2 target. Firstly, scaffold and structural diversity of chemical space for 10 compound databases were explicitly evaluated. Simultaneously, a robust Bayesian classification model was constructed for screening not only compound databases but also their corresponding fragment databases. Although analysis of the scaffold diversity demonstrated a very unevenly distribution of scaffolds over molecules, results showed that our Bayesian model behaved better in screening fragments than molecules. Through a literature retrospective research, several generated fragments with relatively high Bayesian scores indeed exhibit VEGFR-2 biological activity, which strongly proved the effectiveness of fragment VS based on Bayesian categorization models. This investigation of Bayesian-based fragment VS can further emphasize the necessity for enrichment of compound databases employed in lead discovery by amplifying the diversity of databases with novel structures.
针对特定靶点发现新型骨架一直是发现先导化合物过程中最重要但也最具挑战性的目标之一。作为起始点,结合在活性口袋重要区域的骨架更具优势,因为骨架通常具有更大的优化潜力。然而,由于数据库缺乏足够的化学空间多样性以及筛选方法的低效性,发现新型活性骨架仍然是一项巨大的挑战。鉴于基于片段的药物设计和传统虚拟筛选(VS)各自的优缺点,我们提出了一种基于贝叶斯分类的片段VS概念用于发现新型骨架。这项工作通过在VEGFR - 2靶点上的应用对该提议进行了研究。首先,明确评估了10个化合物数据库化学空间的骨架和结构多样性。同时,构建了一个强大的贝叶斯分类模型,用于筛选化合物数据库及其相应的片段数据库。虽然对骨架多样性的分析表明骨架在分子上的分布非常不均匀,但结果显示我们的贝叶斯模型在筛选片段方面比筛选分子表现更好。通过文献回顾研究,几个具有相对较高贝叶斯分数的生成片段确实表现出VEGFR - 2生物活性,这有力地证明了基于贝叶斯分类模型的片段VS的有效性。这种基于贝叶斯的片段VS研究可以通过增加具有新结构的数据库多样性,进一步强调在先导发现中丰富所使用化合物数据库的必要性。